Acetaminophen, Caffeine, and Dihydrocodeine
Pronunciation
(a seet a MIN oh fen, KAF een, & dye hye droe KOE deen)
U.S. Brand Names
Panlor® DC; Panlor® SS
Synonyms
Caffeine, Dihydrocodeine, and Acetaminophen; Dihydrocodeine Bitartrate, Acetaminophen, and Caffeine
Generic Available
No
Use
Relief of moderate to moderately-severe pain
Restrictions
C-III
Pregnancy Risk Factor
C
Pregnancy Implications
Reproduction studies have not been conducted with this combination.
Lactation
Enters breast milk/not recommended
Contraindications
Hypersensitivity to acetaminophen, caffeine, dihydrocodeine, codeine, or any component of the formulation; significant respiratory depression (in unmonitored settings); acute or severe bronchial asthma; hypercapnia; paralytic ileus
Warnings/Precautions
Acetaminophen may cause severe hepatotoxicity in acute overdose; limit acetaminophen to <4 g/day; in addition, chronic daily dosing in adults has resulted in liver damage in some patients. Use with caution in patients with alcoholic liver disease; consuming
3 alcoholic drinks/day may increase the risk of liver damage. Use caution in patients with known G6PD deficiency. Caffeine may cause CNS and cardiovascular stimulation as well as GI irritation in high doses. Dihydrocodeine should be used with caution in patients with hypersensitivity reactions to other phenanthrene derivative opioid agonists (morphine, hydrocodone, hydromorphone, levorphanol, oxycodone, oxymorphone), respiratory diseases including asthma, emphysema, COPD, or severe hepatic or renal insufficiency. Use caution with MAO inhibitors.
This combination should be used with caution in elderly or debilitated patients, hypotension, adrenocortical insufficiency, thyroid disorders, prostatic hyperplasia, urethral stricture, seizure disorder, CNS depression, head injury or increased intracranial pressure. Causes sedation; caution must be used in performing tasks which require alertness (eg, operating machinery or driving). Safety and efficacy in pediatric patients have not been established.
Adverse Reactions
Frequency not defined. Most common reactions with this combination include:
Central nervous system: Dizziness, drowsiness, lightheadedness, sedation
Dermatologic: Pruritus, skin reactions
Gastrointestinal: Constipation, nausea, vomiting
Drug Interactions
Acetaminophen:
Substrate
(minor) of CYP1A2, 2A6, 2C8/9, 2D6, 2E1, 3A4;
Inhibits
CYP3A4 (weak)
Caffeine:
Substrate
of CYP1A2 (major), 2C8/9 (minor), 2D6 (minor), 2E1 (minor), 3A4 (minor);
Inhibits
CYP1A2 (weak), 3A4 (moderate)
Dihydrocodeine:
Substrate
of CYP2D6 (major)
Acetaminophen:
See individual monograph for associated interactions.
Caffeine:
CYP1A2 inhibitors: May increase the levels/effects of caffeine. Example inhibitors include amiodarone, fluvoxamine, ketoconazole, and rofecoxib.
CYP3A4 substrates: Caffeine may increase the levels/effects of CYP3A4 substrates. Example substrates include benzodiazepines, calcium channel blockers, ergot derivatives, mirtazapine, nateglinide, nefazodone, tacrolimus, and venlafaxine.
Quinolone antibiotics (specifically ciprofloxacin, norfloxacin, ofloxacin): Quinolones may increase the level/effects of caffeine.
Dihydrocodeine:
CYP2D6 inhibitors: May decrease the effects of dihydrocodeine. Example inhibitors include chlorpromazine, delavirdine, fluoxetine, miconazole, paroxetine, pergolide, quinidine, quinine, ritonavir, and ropinirole.
Quinidine: Quinidine may decrease the effects of dihydrocodeine.
Ethanol/Nutrition/Herb Interactions
Ethanol: Excessive intake of ethanol may increase the risk of acetaminophen-induced toxicity. Ethanol may also increase CNS depression.
Stability
Store at controlled room temperature of 15°C to 30°C (59°F to 86°F); protect from moisture
Mechanism of Action
Acetaminophen inhibits the synthesis of prostaglandins in the central nervous system and peripherally blocks pain impulse generation; produces antipyresis from inhibition of hypothalamic heat-regulating center.
Caffeine is a CNS stimulant; use with acetaminophen and dihydrocodeine increases the level of analgesia provided by each agent.
Dihydrocodeine binds to opiate receptors in the CNS, causing inhibition of ascending pain pathways, altering the perception of and response to pain; produces generalized CNS depression.
Dosage
Oral: Adults: Relief of pain:
Panlor® DC: 2 capsules every 4 hours as needed; adjust dose based on severity of pain (maximum dose: 10 capsules/24 hours)
Panlor® SS: 1 tablet every 4 hours as needed; adjust dose based on severity of pain (maximum dose: 5 tablets/24 hours)
Dental Health: Effects on Dental Treatment
No significant effects or complications reported
Dental Health: Vasoconstrictor/Local Anesthetic Precautions
No information available to require special precautions
Mental Health: Effects on Mental Status
May cause dizziness or drowsiness
Mental Health: Effects on Psychiatric Treatment
May cause nausea and vomiting; combined use with SSRIs, acetylcholinesterase inhibitors, aripiprazole, or ziprasidone may produce additive effects. The effects of benzodiazepines, mirtazapine, nefazodone, and venlafaxine may be enhanced by caffeine (CYP3A4 inhibitor). Use with chlorpromazine, fluoxetine, paroxetine, pergolide, or ropinirole may decrease the effects of dihydrocodeine. Fluvoxamine may increase the effects of caffeine. Reduce caffeine consumption by 50% or choose an alternative SSRI. Barbiturates, carbamazepine, and excessive intake of ethanol may decrease the effectiveness, as well as increase the hepatotoxic potential of acetaminophen. Combined use with psychotropics may produce additive sedative effects.
Dosage Forms
Capsule (Panlor® DC): Acetaminophen 356.4 mg, caffeine 30 mg, and dihydrocodeine bitartrate 16 mg
Tablet (Panlor® SS): Acetaminophen 712.8 mg, caffeine 60 mg, and dihydrocodeine bitartrate 32 mg
|
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's
accreditation program
is the first of its kind, requiring compliance with 53 standards of quality and accountability, verified by independent audit. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s
editorial process
. A.D.A.M. is also a founding member of Hi-Ethics (www.hiethics.com) and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).
|
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997-2007
A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.
